In a letter to U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, M.D., ACCC raises concern about recent delays in inspections of manufacturing facility that have led to interruptions in the approval of breakthrough therapies. We are particularly concerned when these delays impact novel treatments for diseases without FDA-approved therapies available and those that disproportionately impact minority communities.